BSX to acquire Penumbra for ~$14.5B, deal faces FTC review.

{
  "signal_id": "41856a80-bbf9-4acc-9f3d-265cd7131f7c",
  "signal_type": "sec-10q",
  "signal_subtype": "acquisitionAnnounced",
  "detected_at": "2026-05-05T08:48:22.54+00:00",
  "company": {
    "name": "Boston Scientific",
    "domain": "bostonscientific.com"
  },
  "data": {
    "detail": "BSX announced a definitive agreement to acquire Penumbra for ~$14.5B, to be funded with ~$11B in new debt. The deal is facing regulatory scrutiny from the FTC, which could delay closing and increase compliance costs, creating needs for legal, M&A integration, and treasury management services.",
    "metrics": {
      "dollar_context": "Announced purchase price for Penumbra, Inc.",
      "dollar_millions": 14500
    },
    "summary": "BSX to acquire Penumbra for ~$14.5B, deal faces FTC review.",
    "excerpts": "On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, Inc. (Penumbra), a publicly traded medical technology company primarily focused on thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages. At the time of announcement, the purchase price was valued at $374 per share, or approximately $14.500 billion.",
    "relevance": 1,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000033/bsx-20260331.htm",
    "filing_date": "2026-05-01",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Integration needs coming",
    "signal_category": "strategic"
  }
}

curl https://signals.autobound.ai/v1/signals/41856a80-bbf9-4acc-9f3d-265cd7131f7c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bostonscientific.com","limit":20}'